New investigational antifungal agents for treating invasive fungal infections

Bibliography

• ANAISSIE E, BODEY GP: Nosocomial fungal infections.Old problems and new challenges. Infect. Dis. Clin. North Am. (1989) 3(4):867–882.
   Google Scholar
• DIXON DM, MCNEIL MM, COHEN ML, GELLIN BG, LAMONTAGNE JR: Fungal infections: a growing threat. Public Health Rep. (1996) 1 1 1 (3):226–235.
   Google Scholar
• EDMOND MB, WALLACE SE, MCCLISH DK, PFALLER MA,JONES RN, WENZEL RP: Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin. Infect. Dis. (1999) 29 (2):239–244.
   PubMed Web of Science ®Google Scholar
• MATSUMOTO T, AJELLO L, MATSUDA T, SZANISZLO PJ,WALSH TJ: Developments in hyalohyphomycosis and phaeohyphomycosis. J. Med. Vet. Mycol. (1994) 32 (S1):329–349.
   PubMedGoogle Scholar
• PODNOS YD, ANASTASIO P, DE LA MAZA L, KIM RB: Cerebral phaeohyphomycosis caused by Ramichlo-ridium obovoideum (Ramichloridium mackenzieh: case report. Neurosurgery (1999) 45 (2):372–375.
   PubMed Web of Science ®Google Scholar
• HOLZ RW: The effects of the polyene antibiotics nystatin and amphotericin B on thin lipid membranes. Ann. NY Acad. Sci. (1974) 2 3 5:469–479.
   Google Scholar
• KERRIDGE D: The protoplast membrane and antifungal drugs. In: Fungal Protoplasts: Applications in Biochemistry and Genetics. Peberdy JF, Ferenczy L (Eds.), Marcel Dekker, Inc., New York, USA (1980):135.
   Google Scholar
• GALLIS HA, DREW RH, PICKARD WW: Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. (1990) 12 (2):308–329.
   PubMedGoogle Scholar
• CLEARY JD, HAYMAN J, SHERWOOD J, LASALA GP, PIAZZA-HEPP T: Amphotericin B overdose in pediatric patients with associated cardiac arrest. Ann. Pharmaco-ther. (1993) 2 7 (6):715–719.
   Google Scholar
• SAWAYA BP, BRIGGS JP, SCHNERMANN J: Amphotericin Bnephrotoxicity: the adverse consequences of altered membrane properties. J. Am. Soc. Nephrol. (1995) 6(2):154–164.
   PubMed Web of Science ®Google Scholar
• BRAJTBURG J, BOLARD J: Carrier effects on biological activity of amphotericin B. Clin. Microbiol. Rev. (1996) 9(4):512–531.
   PubMed Web of Science ®Google Scholar
• WONG-BERINGER A, JACOBS RA, GUGLIELMO BJ: lipidformulations of amphotericin B: clinical efficacy and toxicities. Clin. Infect. Dis. (1998) 27(3):603–618.
   PubMed Web of Science ®Google Scholar
• ROBINSON RF, NAHATA MC: A comparative review ofconventional and lipid formulations of amphotericin B. J. Clin. Pharm. Ther. (1999) 24 (4):249–257.
   PubMed Web of Science ®Google Scholar
• HITCHCOCK CA, DICKINSON K, BROWN SB, EVANS EG,ADAMS DJ: Interaction of azole antifungal antibiotics with cytochrome P-450-dependent 14 a-sterol demeth-ylase purified from Candida albicans. Biochem. J. (1990) 266(2):475–480.
   PubMed Web of Science ®Google Scholar
• COMO JA, DISMUKES WE: Oral azole drugs as systemic antifungal therapy. N Engli Med. (1994) 330 (4):263–272.
   PubMed Web of Science ®Google Scholar
• KAUFFMAN CA, CARVER PL: Use of azoles for systemic antifungal therapy. Adv. Pharmacol. (1997) 39:143–189.
   PubMedGoogle Scholar
• AGUNA F, RODRIGUEZ-TUDELA JL, MARTINEZ-SUAREZ JV et al.: Patterns of fluconazole susceptibility in isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis due toCandida albicans. Clin. Infect. Dis. (19 9 7)24(2):124–130.
   Google Scholar
• GOLDMAN M, CLOUD GA, SMEDEMA M et al.: Does long-term itraconazole prophylaxis result in In vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodefi-ciency virus infection? Antimicrob. Agents Chemother. (2000) 44(6):1585–1587.
   PubMed Web of Science ®Google Scholar
• VANDEN BOSSCHE H, MARICHAL P, ODDS FC: Molecularmechanisms of drug resistance in fungi. Trends Microbiol. (1994) 2(10):393–400.
   PubMedGoogle Scholar
• PRASAD R, DE WERGIFOSSE P, GOFFEAU A, BALZI E: Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals. Curr. Genet. (1995) 27 (0320–329.
   PubMed Web of Science ®Google Scholar
• LAMB DC, KELLY DE, SCHUNCK WH et al.: The mutation1315A in Candida albicans sterol 14a-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity. J Biol. Chem. (1997) 272(9):5682–5688.
   PubMed Web of Science ®Google Scholar
• MIYAZAKI H, MIYAZAKI Y, GEBER A et al.: Fluconazoleresistance associated with drug efflux and increased transcription of a drug transporter gene, PDH1, in Candida glabrata. Antimicrob. Agents Chemother. (1998) 42 (7) :1695–1701.
   PubMed Web of Science ®Google Scholar
• DEFONTAINE A, BOUCHARA JP, DECLERK P, PLANCHENAULT C, CHABASSE D, HALLET JN: In-vitro resistance to azoles associated with mitochondrial DNA deficiency in Candida glabrata. J. Med. Microbic]. (1999) 48(7)663–670.
   Google Scholar
• GHANNOUM MA, RICE LB: An tifun gal agents: mode ofaction, mechanisms of resistance and correlation of these mechanisms with bacterial resistance. Clin. Microbiol. Rev. (1999)12 (4) :501–517.
   PubMed Web of Science ®Google Scholar
• HOESLEY C, DISMUKES WE: Overview of oral azole drugs as systemic antifungal therapy. Semin. Resp. Grit. Care Med. (1997) 18(3):301–309.
   Web of Science ®Google Scholar
• POLAK A, SCHOLER HJ: Mode of action of 5-fluorocytosine and mechanisms of resistance. Chemotherapy (1975) 21:113–130.
   PubMed Web of Science ®Google Scholar
• DIASIO RB, BENNETT JE, MYERS CE: Mode of action of 5-fluorocytosine. Biochem. Pharmacol. (1978) 27 (5):703–707.
   PubMed Web of Science ®Google Scholar
• MEHTA RT, HOPFER RL, GUNNER LA, JULIANO RL, LOPEZ-BERESTEIN G: Formulation, toxicity and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrob. Agents Chemother. (1987) 31(12):1897–1900.
   PubMed Web of Science ®Google Scholar
• MEHTA RT, HOPFER RL, MCQUEEN T, JULIANO RL, LOPEZ-BERESTEIN G: Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections. Antimicrob. Agents Chemother. (1987) 31 (12):1901–1903.
   PubMed Web of Science ®Google Scholar
• WASAN KM, RAMASWAMY M, CASSIDY SM, KAZEMI M, STROBEL FW, THIES RL: Physical characteristics and lipoprotein distribution of liposomal nystatin in human plasma. Antimicrob. Agents Chemother. (1997) 41 (9):1871–1875.
   PubMed Web of Science ®Google Scholar
• OAKLEY KL, MOORE CB, DENNING DW: Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex and itraconazole. Antimicrob. Agents Chemother. (1999) 43(5):1264–1266.
   PubMed Web of Science ®Google Scholar
• GROLL AH, PETRAITIS V, PETRAITIENE R et al.: Safety and efficacy of multilamellar liposomal nystatin against disseminated candidiasis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. (1999) 43 (10):2463–2467.
   PubMed Web of Science ®Google Scholar
• DENNING DW, WARN P: Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B. Antimicrob. Agents Chemother. (1999) 43(10:2592–2599.
   PubMed Web of Science ®Google Scholar
• RIOS A, ROSENBLUM M, CROFOOT G, LENK RP, HAYMANA, LOPEZ-BERESTEIN G: Pharmacokinetics of liposomal nystatin in patients with human immuno-deficiency virus infection. J. Infect. Dis. (1993) 168 (1):253–254.
   PubMed Web of Science ®Google Scholar
• WALLACE T AND THE NYOTRAN STUDY GROUP: In vitroantifungal activity of Nyotran against clinical isolates. Abstracts of the 14th Conference of the International Society for Human and Animal Mycology. Buenos Aires, Argentina. (2000).
   Google Scholar
• JESSUP C, WALLACE T, GHANNOUM MA: An in vitro interaction study with Nyotran (liposomal Nystatin) and conventional antifungals, antibiotics, antivirals and immunosuppressive drugs against common fungal pathogens. Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology. San Francisco, USA (1999).
   Google Scholar
• VAN ETTEN EW, VAN VIANEN W, ROOVERS P, FREDERIKP: Mild heating of amphotericin B-desoxycholate: effects on ultrastructure, In vitro activity and toxicity and therapeutic efficacy in severe candidiasis in leukopenic mice. Antimicrob. Agents Chemother. (2000) 44 (6):1598–1603.
   PubMed Web of Science ®Google Scholar
• WALKER S, TAILOR SA, LEE M, LOUIE L, LOUIE M, SIMOR AE: Arnphotericin B in lipid emulsion: stability, compatibility and in vitro antifungal activity. Antimi-crob. Agents Chemother. (1998) 42 (4):762–766.
   PubMed Web of Science ®Google Scholar
• SHADKCHAN Y, SEGAL E: Antifungal activity of amphotericin B-lipid admixtures in experimental systemic candidosis in naive mice. J. Antimicrob. Chemother. (1999) 44 (6) :787–790.
   PubMed Web of Science ®Google Scholar
• BARQUIST E, FEIN E, SHADICK D, JOHNSON J, CLARK J,SHATZ D: A randomized prospective trial of amphotericin B lipid emulsion versus dextrose colloidal solution in critically ill patients. J Trauma (1999) 47 (2):336–340.
   PubMed Web of Science ®Google Scholar
• KOHNO S, OTSUBO T, HARA K, TOMII Y, SEKI J: Anewantifungal drug delivery system, lipid nanosphere encapsulating amphotericin B (INS-ArnB), its evalua-tion in the rat model of invasive pulmonary aspergil-losis. Program and Abstracts of the 35th Intel-science Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology. Washington DC, USA (1995).
   Google Scholar
• HOSSAIN MA, MAESAKI S, KAKEYA H et al.: Efficacy ofNS-718, a novel lipid nanosphere-encapsulated amphotericin B, against Cryptococcus neoformans. Antimicrob. Agents Chemother. (1998) 42 (7):1722–1725.
   PubMed Web of Science ®Google Scholar
• OTSUBO T, MAESAKI S, HOSSAIN MA et al.: In vitro andin vivo activities of NS-718, a new lipid nanosphere incorporating amphotericin B, against Aspergillus fumigatus. Antimicrob. Agents Chemother. (1999) 43 (3):471–475.
   PubMed Web of Science ®Google Scholar
• HOSSAIN MA, MAESAKI S, RAZZAQUE MS et al.: Attenua-tion of nephrotoxicity by a novel lipid nanosphere incorporating amphotericin B, NS-718. j Antimicrob. Chemother. (2000) (In Press).
   Google Scholar
• VAN ETTEN EW, TEN KATE MT, STEARNE LE, BAKKER-WOUDENBERG IA: Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity and efficacy in systemic candidiasis in leukopenic mice. Antimicrob. Agents Chemother. (1995) 39 (9):1954–1958.
   PubMed Web of Science ®Google Scholar
• OTSUBO T, MARUYAMA K, MAESAKI S et al.: Long-circulating immunoliposomal amphotericin B against invasive pulmonary aspergillosis in mice. Antimicrob. Agents Chemother. (1998) 42(1)40–44.
   Google Scholar
• ZARIF L, GRAYBILL JR, PERLIN D, NAJVAR L, BOCANEGRAR, MANNINO RJ: Antifungal activity of amphotericin B cochleates against Candida albicans infection in a © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (2000) 9(8) mouse model. Antimicrob. Agents Chemother. (2000) 44(6):1463–1469.
   Google Scholar
• BELANGER P, NAST CC, FRATTI R, SANATI H,GHANNOUM M: Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species. Antimicrob. Agents Chemother. (1997) 41 (8):1840–1842.
   PubMed Web of Science ®Google Scholar
• KOUL A, VITULLO J, REYES G, GHANNOUM M: Effects ofvoriconazole on Candida glabrata in vitro. J. Antimi-crob. Chemother. (1999) 4 4 (1):109–112.
   Google Scholar
• NGUYEN MH, YU CY: Voriconazole againstfluconazole-susceptible and resistant Candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole. J. Antimicrob. Chemother. (1998) 42(2):253–256.
   PubMed Web of Science ®Google Scholar
• SANATI H, BELANGER P, FRATTI R, GHANNOUM M: A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob. Agents Chemother. (1997) 41 (11):2492–2496.
   PubMed Web of Science ®Google Scholar
• BRUMMER E, KAMEI K, MIYAJI M: Anticryptococcalactivity of voriconazole against Cryptococcus neofor-mans var. gatti vs. var. neoformans: comparison with fluconazole and effect of human serum. Mycopathologia (1998) 142 (1):3–7.
   Google Scholar
• GARCIA MT, LLORENTE MT, LIMA JE, MINGUEZ F, DELMORAL F, PRIETO J: Activity of voriconazole: post-antifungal effect, effects of low concentrations and of pretreatment on the susceptibility of Candida albicans to leucocytes. Scand. J. Infect. Dis. (1999) 31 (5):501–504.
   PubMed Web of Science ®Google Scholar
• MURPHY M, BERNARD EM, ISHIMARU T, ARMSTRONG D:Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. (1997) 41 (3):696–698.
   PubMed Web of Science ®Google Scholar
• ESPINEL-INGROFF A: In vitro activity of the new triazolevoriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol. (1998) 36 (1) :198–202.
   PubMed Web of Science ®Google Scholar
• SUTTON DA, SANCHE SE, REVANKAR SG, FOTHERGILLAW, RINALDI MG: In vitro amphotericin B resistance in clinical isolates of AspergiBus terreus, with a head-to-head comparison to voriconazole. j Gun. Mkrobiol. (1999) 37 (7):2343–2345.
   Web of Science ®Google Scholar
• PFALLER MA, ZHANG J, MESSER SA et al: In vitro activi-ties of voriconazole, fluconazole and itraconazole against 566 clinical isolates of Cryptococcus neofor-mans from the United States and Africa. Antimicrob. Agents Chemother. (1999) 43:169–171.
   PubMed Web of Science ®Google Scholar
• MCGINNIS MR, PASARELL L, SUTTON DA, FOTHERGILLAW, COOPER JR. CR, RINALDI MG: In vitro activity of voriconazole against selected fungi. Med. Mycol. (1998) 3 6 (4):239–242.
   Google Scholar
• FRATTI RA, BELANGER PH, SANATI H, GHANNOUM MA: The effect of the new triazole, voriconazole (UK-109,496), on the interactions of Candida albicans and Candida krusei with endothelial cells. J. Chemother. (1998) 1 0 (1) :7–16.
   Google Scholar
• GHANNOUM MA, OKOGBULE-WONODI I, BHAT N, SANATI H: Antifungal activity of voriconazole (UK-109,496), fluconazole and amphotericin B against hematogenous Candida krusei infection in neutro-p enic guinea pig model. J. Chemother. (1999) 11 (1):34–39.
   PubMed Web of Science ®Google Scholar
• HEGENER P, TROKE PF, FATKENHEUER G, DIEHL V, RUHNKE M: Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS (1998) 12(16):2227–2228.
   PubMed Web of Science ®Google Scholar
• DENNING D, DEL FAVERO A, GLUCKMAN E et al.: UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in acute invasive Asp ergillosis. Program and Abstracts of the 35th Intel-science Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology Washington DC, USA (1995).
   Google Scholar
• LAW D, MOORE CB, DENNING DW: Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. Antimicrob. Agents Chemother. (1997) 41 (10):2310–2311.
   PubMed Web of Science ®Google Scholar
• PERFECT JR, COX GM, DODGE RK, SCHELL WA: In vitro and in vivo efficacies of the azole 5CH56592 against Cryptococcus neoformans. Antimicrob. Agents Chemother. (1996) 40(8):1910–1913.
   PubMed Web of Science ®Google Scholar
• OAKLEY KL, MORRISSEY G, DENNING DW: Efficacy of SCH 56592 in a temporarily neutropenic murine model of invasive Aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob. Agents Chemother. (1997) 41:1504–1507.
   PubMed Web of Science ®Google Scholar
• SUGAR AM, LIU XP: In vitro activity of SCH 56592 against Blastomyces dermatitidis. Antimicrob. Agents Chemother. (1996) 40:1314–1316.
   PubMed Web of Science ®Google Scholar
• LUTZ JE, CLEMONS KV, ARISTIZABAL BH, STEVENS DA: Activity of the triazole 5CH56592 against disseminated murine coccidioidomycosis. Antimicrob. Agents Chemother. (1997) 41:1558–1561.
   PubMed Web of Science ®Google Scholar
• CONNOLLY P, WHEAT J, SCHNIZLEIN-BICK C et al.: Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. Antimicrob. Agents Chemother. (1999) 43:322–328.
   PubMed Web of Science ®Google Scholar
• BARCHIESI F, ARZENI D, FOTHERGILL AW et al.: In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens. Antimicrob. Agents Chemother. (2000) 44 (1):226–229.
   PubMed Web of Science ®Google Scholar
• HOSSAIN MA, MAESAKI S, MITSUTAKE K et al.: In-vitro and in-vivo activities of 5CH56592 against Crypto-coccus neoformans. J. Antimicrob. Chemother. (1999) 44 (6):827–829.
   PubMed Web of Science ®Google Scholar
• GRAYBILL JR, BOCANEGRA R, NAJVAR LK, LUTHER MF,LOEBENBERG D: 5CH56592 treatment of murine © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (2000) 9(8) invasive aspergillosis. j Antimicrob. Chemother. (1998) 42 (4):539–542.
   Google Scholar
• KIRKPATRICK WR, MCATEE RK, FOTHERGILL AW, LOEBENBERG D, RINALDI MG, PATTERSON TF: Efficacy of SCH56592 in a rabbit model of invasive aspergil-losis. Antimicrob. Agents Chemother. (2000) 44(3) :780–782.
   PubMed Web of Science ®Google Scholar
• LOZANO-CHIU M, ARIKAN S, PAETZNICK VL, ANAISSIE EJ,LOEBENBERG D, REX JH: Treatment of murine fusario-sis with SCH56592. Antimicrob. Agents Chemother. (1999) 43 (3):589–591.
   PubMed Web of Science ®Google Scholar
• PUJOL I, GUARRO J, GENE J, SALA J: In-vitro antifungalsusceptibility of clinical and environmental Fusarium spp. strains. J. Antimicrob. Chemother. (1997) 39 (2):163–167.
   PubMed Web of Science ®Google Scholar
• AL-ABDELY HM, NAJVAR L, BOCANEGRA R et al.: SCH56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ('Ramichlo-ridium mackenziel). Antimicrob. Agents Chemother. (2000) 44(5):1159–1162.
   PubMed Web of Science ®Google Scholar
• NOMEIR AA, KUMARI P, HILBERT MJ et al.: Pharmacoki-netics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs and cynomolgus monkeys. Antimicrob. Agents Chemother. (2000) 44 (3) :727–731.
   PubMed Web of Science ®Google Scholar
• FUNG-TOMC JC, HUCZKO E, MINASSIAN B, BONNER DP:In vitro activity of a new oral triazole, BMS-207147 (ER-30346). Antimicrob. Agents Chemother. (1998) 42 (2):313–318.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, MESSER SA, HOLLIS RJ et al: In vitro suscep-tibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592 and voriconazole. Antimicrob. Agents Chemother. (1998) 42 (12):3242–3244.
   PubMed Web of Science ®Google Scholar
• FUNG-TOMC JC, WHITE TC, MINASSIAN B, HUCZKO E,BONNER DP: In vitro antifungal activity of BMS-207147 and itraconazole against yeast strains that are non-susceptible to fluconazole. Diagn. Microbiol. Infect. Dis. (1999) 35(2):163–167.
   PubMed Web of Science ®Google Scholar
• MOORE CB, WALLS CM, DENNING DW: In vitro activityof the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B. Antimicrob. Agents Chemother. (2000) 44 (2) :441–443.
   PubMed Web of Science ®Google Scholar
• SHOCK K, MARINO S, BAUMGARTNER, ANDRIOLE V: Efficacy of a new triazole, BMS-207174, in a model of invasive aspergillosis in immunosuppressed, neutro-p enic rabbits. Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology. San Diego, USA (1998).
   Google Scholar
• REYES G, LONG L, GHANNOUM M: Efficacy of BMS-207147 on Trichophyton mentagrophytes-Dermatophytosis in guinea pig model. Abstracts of the 14th Conference of the International Society for Human and Animal Mycology. Buenos Aires, Argentina (2000).
   Google Scholar
• NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS: Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Labora-tory Standards, Wayne, PA, USA (1997).
   Google Scholar
• JOHNSON EM, SZEKELY A, WARNOCK DW: In vitro activity of Syn-2869, a novel triazole agent, against emerging and less common mold pathogens. Antimi-crob. Agents Chemother. (1999) 43 (5):1260–1263.
   PubMed Web of Science ®Google Scholar
• SCHELL WA, DE ALMEIDA GM, DODGE RK, OKONOGI K, PERFECT JR: In vitro and in vivo efficacy of the triazole TAK-187 against Cryptococcus neoformans. Antimi-crob. Agents Chemother. (1998) 42(10):2630–2632.
   PubMed Web of Science ®Google Scholar
• SURARIT R, GOPAL PK, SHEPHERD MG: Evidence for a glycosidic linkage between chitin and glucan in the cell wall of Candida albicans. J. Gen. Microbiol. (1988) 134 (Pt 6):1723–1730.
   PubMedGoogle Scholar
• HOSSAIN MA, MIYAZAKI T, MITSUTAKE K et al.: Comparison between Wako-WB003 and Fungitec G tests for detection of (13)-3-D-glucan in systemic mycosis. J. Clin. Lab. Anal. (1997) 11 (2):73–77.
   PubMed Web of Science ®Google Scholar
• YOSHIDA M, OBAYASHI T, IWAMA A et al.: Detection of plasma (1 3)-13-D-glucan in patients with Fusarium, Trichosporon, Saccharomyces and Acremonium fungaemias. J. Med. Vet. Mycol. (1997) 35(5):371–374.
   PubMedGoogle Scholar
• DEBONO M, GORDEE RS: Antibiotics that inhibit fungal cell wall development. Ann. Rev. Microbiol. (1994) 48:471–497.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, MARCO F, MESSER SA, JONES RN: In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus and other filamen-tous fungi. Diagn. Microbiol. Infect. Dis. (1998) 30 (4):251–255.
   PubMed Web of Science ®Google Scholar
• BARTIZAL K, GILL CJ, ABRUZZO GK et al.: In vitro preclinical evaluation studies with the echinocandin anMK-0991 (L-743,872). Antimicrob. AgentsChemother. (1997) 41(10:2326–2332.
   PubMed Web of Science ®Google Scholar
• GRAYBILL JR, NAJVAR LK, MONTALBO EM, BARCHIESI FJ, LUTHER MF, RINALDI MG: Treatment of histoplasmosis with MK-991 (L-743,872). Antimicrob. Agents Chemother. (1998) 42(0:151–153.
   PubMed Web of Science ®Google Scholar
• POWLES MA, LIBERATOR P, ANDERSON J et al.: Efficacy of MK-991 (L-743,872), a semisynthetic pneumo-candin, in murine models of Pneumocystis carinii. Antimicrob. Agents Chemother. (1998) 42 (8) :1985–1989.
   PubMed Web of Science ®Google Scholar
• KRISHNARAO TV, GALGIANI JN: Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991 and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob. Agents Chemother. (1997) 41 (9) :1957–1960.
   PubMed Web of Science ®Google Scholar
• PETRAITIENE R, PETRAITIS V, GROLL AH et al.:Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob. Agents Chemother. (1999) 43 (9):2148–2155. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (2000) 9(8)
   Google Scholar
• ESPINEL-INGROFF A: Comparison of In vitro activitiesof the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportun-istic filamentous and dimorphic fungi and yeasts. J Microbiol. (1998) 36(102950–2956.
   Web of Science ®Google Scholar
• PETRAITIS V, PETRAITIENE R, GROLL AH et al.:Antifungal efficacy, safety and single-dose pharma-cokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. (1998) 42(10:2898–2905.
   PubMed Web of Science ®Google Scholar
• BARTLETT MS, CURRENT WL, GOHEEN MP et al.: Semisynthetic echinocandins affect cell wall deposi-tion of Pneumocystis carinii in vitro and in vivo. Antimicrob. Agents Chemother. (1996) 40(8):1811–1816.
   PubMed Web of Science ®Google Scholar
• TAWARA S, IKEDA F, MAKI K et al: In vitro activities of anew lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob. Agents Chemother. (2000) 44(0:57–62.
   PubMed Web of Science ®Google Scholar
• MAESAKI S, HOSSAIN MA, MIYAZAKI Y, TOMONO K, TASHIRO T, KOHNO S: Efficacy of FK463, a (1,3)-13-D-glucan synthase inhibitor, in disseminated azole-resistant Candida albicans infection in mice. Antimicrob. Agents Chemother. (2000) 44 (6) :1728–1730.
   PubMed Web of Science ®Google Scholar
• NILIUS AM, RANEY PM, HENSEY-RUDLOFF DM, WANG W, LI Q, FLAMM RK: In vitroactivity of A-192411.29, a novel antifungal lipopeptide. Antimicrob. Agents Chemother. (2000) 44 (5) :1242–1246.
   Google Scholar
• HAWSER S, BORGONOVI M, MARKUS A, ISERT D: Mulundocandin, an echinocandin-like lip op ep tide antifungal agent: biological activities in vitro. J. Antibiot. (Tokyo) (1999) 52(3):305–310.
   PubMed Web of Science ®Google Scholar
• HECTOR RF, ZIMMER BL, PAPPAGIANIS D: Evaluation of nikkomycins X and Z in murine models of coccidioi-domycosis, histoplasmosis and blastomycosis. Antimi-crob. Agents Chemother. (1990) 34(4):587–593.
   PubMed Web of Science ®Google Scholar
• CLEMONS KV, STEVENS DA: Efficacy of nikkomycin Z against experimental pulmonary blastomycosis. Antimicrob. Agents Chemother. (1997) 41(9)2026–2028.
   Google Scholar
• LI RK, RINALDI MG: In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole. Antimicrob. Agents Chemother. (1999) 43:1401–1405.
   PubMed Web of Science ®Google Scholar
• GRAYBILL JR, NAJVAR LK, BOCANEGRA R, HECTOR RF, LUTHER MF: Efficacy of nikkomycin Z in the treatment of murine histoplasmosis. Antimicrob. Agents Chemother. (1998) 42 (9):2371–2374.
   PubMed Web of Science ®Google Scholar
• GOLDBERG J, CONNOLLY P, SCHNIZLEIN-BICK C et al: Comparison of nikkomycin Z with amphotericin B and itraconazole for treatment of histoplasmosis in a murine model. Antimicrob. Agents Chemother. (2000) 44 (6) :1624–1629.
   PubMed Web of Science ®Google Scholar
• WATABE H, MIKUNIYA T, INOUYE S et al: Antifungal antibiotic benanomicin A increases susceptibility of Candida albicans to phagocytosis by murine macrophages. J. Antibiot. (Tokyo) (1996) 49 (12):1221–1225.
   PubMed Web of Science ®Google Scholar
• WATANABE M, GOMI S, TOHYAMA H et al: Binding of benanomicin A to fungal cells in reference to its fungicidal action. J. Antibiot. (Tokyo) (1 9 9 6) 49 (4):366–373.
   Google Scholar
• FUNG-TOMC JC, MINASSIAN B, HUCZKO E, KOLEK B, BONNER DP, KESSLER RE: In vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184. Antimicrob. Agents Chemother. (1995) 39(2)295–300.
   Google Scholar
• OAKLEY KL, MOORE CB, DENNING DW: Activity of pradimicin BMS-181184 against Aspergillus spp. Int. J. Antimicrob. Agents. (1999) 12(3):267–269.
   PubMed Web of Science ®Google Scholar
• WATANABE M, HIRATANI T, UCHIDA K etal.: The in-vitro activity of an antifungal antibiotic benanomicin A in comparison with amphotericin B. J. Antimicrob. Chemother. (1996) 38(6):1073–1077.
   Google Scholar
• OHTSUKA K, WATANABE M, ORIKASA Y et al.: The in-vivo activity of an antifungal antibiotic, benanomicin A, in comparison with amphotericin B and fluconazole. J. Antimicrob. Chemother. (1997) 39 (1):71–77.
   PubMed Web of Science ®Google Scholar
• HANCOCK RE: Peptide antibiotics. Lancet (1997) 349 :418–422.
   PubMed Web of Science ®Google Scholar
• ALCOULOUMRE MS, GHANNOUM MA, IBRAHIM AS, SELSTED ME, EDWARDS JE JR.: Fungicidal properties of defensin NP-1 and activity against Cryptococcus neoformans in vitro. Antimicrob. Agents Chemother. (1993) 37 (12):2628–2632.
   Google Scholar
• HONG SY, OH JE, LEE KH: In vitro antifungal activity and cytotoxicity of a novel membrane-active peptide. Antimicrob. Agents Chemother. (1999) 43 (7):1704–1707.
   PubMed Web of Science ®Google Scholar
• SITU H, BOBEK LA: In vitro assessment of antifungal therapeutic potential of salivary histatin-5, two variants of histatin-5 and salivary mucin (MUC7) domain 1. Antimicrob. Agents Chemother. (2000) 44 (6):1485–1493.
   PubMed Web of Science ®Google Scholar
• GRAYBILL JR, NAJVAR L, FOTHERGILL A, BOCANEGRA R, DE LAS HERAS FG: Activities of sordarins in murine histoplasmosis. Antimicrob. Agents Chemother. (1999) 43 (7):1716–1718.
   PubMed Web of Science ®Google Scholar